Compare BANC & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BANC | NUVB |
|---|---|---|
| Founded | 1941 | 2018 |
| Country | United States | United States |
| Employees | 1903 | 291 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 1.6B |
| IPO Year | N/A | N/A |
| Metric | BANC | NUVB |
|---|---|---|
| Price | $16.77 | $4.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $21.39 | $11.22 |
| AVG Volume (30 Days) | 2.4M | ★ 4.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.64 | $182.76 |
| Revenue Next Year | $8.03 | $91.83 |
| P/E Ratio | $17.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.52 | $1.57 |
| 52 Week High | $21.61 | $9.75 |
| Indicator | BANC | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 27.11 | 34.56 |
| Support Level | $16.28 | $4.04 |
| Resistance Level | $17.40 | $5.73 |
| Average True Range (ATR) | 0.61 | 0.32 |
| MACD | -0.19 | -0.04 |
| Stochastic Oscillator | 12.15 | 16.38 |
Banc of California Inc is a financial holding company. It offers banking and financial services. Its services include banking services, lending services, and private banking services. Its deposit and banking product and service offerings include checking, savings, money market, certificates of deposit, and retirement accounts. Lending activities are focused on providing financing to California's diverse private businesses, entrepreneurs, and communities, and loans are often secured by California commercial and residential real estate. The company has one reportable segment named Commercial banking.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.